SCHEMBL570690

SCHEMBL570690

Cc1ccsc1-c1[c]nccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 10/20 0.49
CYP3A4 P08684 4/20 0.49
CYP2C19 P33261 4/20 0.49
CYP2B6 P20813 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2E1 P05181 1/20 0.49
NISCH Q9Y2I1 1/20 0.40
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 3/20 0.35
CYP1A2 P05177 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
PSMD14 O00487 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909130 0.71
SCHEMBL1521856 0.70 CYP2A6 (0.40) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL2342778 0.70 PDPK1 (0.47) CYP2A6ALDH1A1NPC1RAB9A
SCHEMBL722595 0.68 CYP2A6 (0.56) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL661463 0.68 CYP3A4 (0.46) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL14886177 0.67 CYP2A6 (0.52) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL14635181 0.67 NAMPT (0.33) NAMPT
SCHEMBL3137125 0.67 RECQL (0.41) CYP2D6ALDH1A1HPGDKDM4ECYP1A2
SCHEMBL3145458 0.67 CYP3A4 (0.50) CYP2A6CYP3A4CYP2B6CYP2C9CYP2E1
SCHEMBL9773332 0.66 CYP2A6 (0.41) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196905-A1 SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-08-02 US claimed
WO-2012019093-A1 SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-02-09 WO claimed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US claimed
WO-2005066162-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2005-07-21 WO claimed
US-8906943-B2 Synthetic compounds and methods to decrease nicotine self-administration HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2014-12-09 US disclosed
US-8609708-B2 Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2013-12-17 US disclosed
US-20120196905-A1 SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-08-02 US disclosed
WO-2012019093-A1 SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-02-09 WO disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
WO-2005066162-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP3A4 45/4885CYP2C19 41/4885
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP3A4 45/4885CYP2C19 41/4885
US-20120196905-A1 SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION SLC6A3, NNT, SLC6A2 CYP2A6 1009/4885CYP3A4 2144/4885CYP2C19 3571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.